.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
UBS
Covington
Healthtrust
Chubb
Harvard Business School
Cantor Fitzgerald
Colorcon
Boehringer Ingelheim
Queensland Health

Generated: September 22, 2017

DrugPatentWatch Database Preview

Eliglustat tartrate - Generic Drug Details

« Back to Dashboard

What are the generic sources for eliglustat tartrate and what is the scope of eliglustat tartrate freedom to operate?

Eliglustat tartrate
is the generic ingredient in one branded drug marketed by Genzyme Corp and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Eliglustat tartrate has forty patent family members in fifteen countries.

There is one drug master file entry for eliglustat tartrate. One supplier is listed for this compound.

Summary for Generic Name: eliglustat tartrate

Tradenames:1
Patents:3
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Suppliers / Packagers: see list1
Clinical Trials: see list144
Drug Prices:see low prices
DailyMed Link:eliglustat tartrate at DailyMed
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► SubscribeY ► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe ► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
Genzyme Corp
CERDELGA
eliglustat tartrate
CAPSULE;ORAL205494-001Aug 19, 2014RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: eliglustat tartrate

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,051,598 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
6,030,995 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
6,855,830 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
8,779,163Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors► Subscribe
6,255,336 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
6,890,949 Amino ceramide-like compounds and therapeutic methods of use► Subscribe
8,138,353Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
7,253,185Amino ceramide-like compounds and therapeutic methods of use► Subscribe
5,916,911 Amino ceramide--like compounds and therapeutic methods of use► Subscribe
7,763,738Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: eliglustat tartrate

Country Document Number Estimated Expiration
Portugal2067775► Subscribe
European Patent Office1196406► Subscribe
Japan5227348► Subscribe
Hong Kong1132267► Subscribe
European Patent Office1409467► Subscribe
Cyprus1113919► Subscribe
European Patent Office2266968► Subscribe
Canada2453978► Subscribe
Australia5929600► Subscribe
Brazil0211379► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: ELIGLUSTAT TARTRATE

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C0036France► SubscribePRODUCT NAME: ELIGLUSTAT,EVENTUELLEMENT SOUS FORME D'UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE; REGISTRATION NO/DATE: EU/1/14/974 20150119
00738Netherlands► SubscribePRODUCT NAME: ELIGLUSTAT, OF FYSIOLOGISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/974 20150119
/2015Austria► SubscribePRODUCT NAME: ELIGLUSTAT, OPTIONAL IN DER FORM EINES PHYSIOLOGISCH AKZEPTABLEN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
717Luxembourg► SubscribePRODUCT NAME: ELIGLUSTAT, EVENTUELLEMENT SOUS LA FORME D UN SEL PHYSIOLOGIQUEMENT ACCEPTABLE. FIRST REGISTRATION: 20150121
15/027Ireland► SubscribePRODUCT NAME: ELIGLUSTAT, OPTIONALLY IN THE FORM OF A PHYSIOLOGICALLY ACCEPTABLE SALT; REGISTRATION NO/DATE: EU/1/14/974 20150119
4 4-2015Slovakia► SubscribePRODUCT NAME: ELIGLUSTAT (VO FORME TARTRATU); REGISTRATION NO/DATE: EU/1/14/974 20150121
2015 00035Denmark► SubscribePRODUCT NAME: ELIGLUSTAT, EVENTUELT I FORM AF ET FYSIOLOGISK ACCEPTABELT SALT, HERUNDER ELIGLUSTAT (SOM TARTRAT); REG. NO/DATE: EU/1/14/974 20150119
0150027 00161Estonia► SubscribePRODUCT NAME: ELIGLUSTAAT;REG NO/DATE: EU/1/14/974 21.01.2015
90029-3Sweden► SubscribePRODUCT NAME: ELIGLUSTAT, VALFRITT I FORM AV ETT FYSIOLOGISKT GODTAGBART SALT; REG. NO/DATE: EU/1/14/974 20150121
2015000051Germany► SubscribePRODUCT NAME: ELIGLUSTAT, GGF. IN FORM EINES PHYSIOLOGISCH ANNEHMBAREN SALZES; REGISTRATION NO/DATE: EU/1/14/974 20150119
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
Chinese Patent Office
AstraZeneca
Daiichi Sankyo
Cipla
US Department of Justice
Cerilliant
Mallinckrodt
Baxter
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot